Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib and Durvalumab in Primary CNS Lymphoma
NCT04462328Phase 1Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2021
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of acalabrutinib tablet (Variant 1) and durvalumab in primary central nervous system lymphoma (PCNSL) (3 arms), sponsored by Washington University School of Medicine. Primary endpoints: Tolerability as defined as tolerable dose at 12 weeks and Safety as defined by frequency of toxicities assessed by CTCAE v 5.0 at 90 days. Started Apr 2021; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)durvalumab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT04462328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04462328.